BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 5
• 6
• 7
• 8
• 9
• 12
• 13
• 14
• 15
• 16
• 19
• 20
• 21
• 22
• 23
• 26
• 27
• 28
• 29
• 30

• Cancel your Unlimited Jobs plan

  Please provide the information to confirm your Unlimited Jobs cancellation.
  For additional support, please contact us at support@biospace.com

  August 14, 2024
• 

  Opinion

  Invest in Domestic Manufacturing to Onshore America’s Biotech Supply Chain

  As the U.S. moves away from reliance on Chinese CDMOs, Southern cities provide a model for how we can bolster domestic production capacity.

  August 14, 2024

   · 

  5 min read

   · 

  Josh Carpenter
• 

  IRA

  Experts Analyze IRA’s Effect as the Industry Awaits Negotiated CMS Drug Prices

  The new Medicare prices for the first 10 drugs negotiated under the Inflation Reduction Act are expected soon. Analysts and researchers are divided on the long-term effects of the law.

  August 14, 2024

   · 

  6 min read

   · 

  Tyler Patchen
• 

  Layoffs

  Grail Lays Off About 350 Employees, Puts Brakes on New Hires

  The layoffs will help extend the company’s cash runway from the second half of 2026 into 2028.

  August 14, 2024

   · 

  1 min read

   · 

  Angela Gabriel
• 

  Career Advice

  Career Coach: How to Craft an Industry Resume After a Career in Academia

  Plus, learn how to handle vacation time in a new job and navigate the stress of a recent promotion to leadership.

  August 14, 2024

   · 

  7 min read

   · 

  Carina Clingman
• 

  Business

  Illumina Lays Out Growth Roadmap After Grail Divestment

  In a bid to win back investor confidence, Illumina on Tuesday unveiled a three-year growth plan focused on easier DNA sequencing and improved data analysis for customers.

  August 14, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Gene therapy

  Lilly Opens $700M R&D Center in Boston for Genetic Medicines

  Eli Lilly’s new research and development facility in Boston’s Seaport district will focus on DNA- and RNA-based therapies, as well as other priority areas such as diabetes and obesity.

  August 14, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Business

  Biotech Industry Overcomes Slump, Adapts to New Normal

  M&A activity surges and IPOs return as the biotech industry navigates a changing business landscape marked by strategic consolidation and renewed investor focus on innovation.

  August 14, 2024

   · 

  6 min read

   · 

  Ana Mulero
• 

  Podcast

  Lykos Rejection, Pfizer’s RSV Win, Lilly Vs. Novo and More

  Lykos Therapeutics will ask the FDA to reconsider its rejection of the company’s MDMA-assisted PTSD therapy, Pfizer scores positive Phase III results for its RSV vaccine, a roundup of Q2 earnings season and more.

  August 14, 2024

   · 

  1 min read

   · 

  Heather McKenzie
• 

  Approvals

  AstraZeneca’s Imfinzi-Lynparza Combo Wins Landmark EU Nod for Endometrial Cancer

  The European Union has approved the first-ever combination therapy consisting of an immunotherapy and a PARP inhibitor for the treatment of endometrial cancer, AstraZeneca announced Wednesday.

  August 14, 2024

   · 

  2 min read

   · 

  Tristan Manalac